Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
63.86 USD
↗ 0.11 (0.17%)AT CLOSE (03:59 PM EDT)
63.97
↗ 0.11 (0.17%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
63.97
↗ 0.11 (0.17%)
🔴Market: CLOSED

Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $63.86. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 23, 2026.

Open?$63.50
High?$63.97
Low?$63.01
Prev. Close?$63.75
Volume?4.0M
Avg. Volume?3.1M
VWAP?$63.63
Rel. Volume?1.31x
Bid / Ask
Bid?$60.00 × 200
Ask?$64.00 × 100
Spread?$4.00
Midpoint?$62.00
Valuation & Ratios
Market Cap?28.4B
Shares Out?445.3M
Float?437.7M
Float %?98.3%
P/E Ratio?34.89
P/B Ratio?4.16
EPS?$1.83
Dividend?1.40%
Ex-Dividend?2026-11-13
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
28.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
47
Momentum?
73
Short Sent.?
73
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.32Grey
Confidence?76%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.94%Low
Short Interest?12.9M
Days to Cover?4.4
Free Float437.7M
Avg Daily Volume2.9M
Settlement Date2026-09-30
Financial Health
Current Ratio?2.80Strong
Quick Ratio?2.80Strong
Cash Ratio?1.29Strong
Debt/Equity?1.33Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
Peers
100
S&P
22
34.9PRICEY▾
P/B?
Peers
100
S&P
43
4.16FAIR▾
P/S?
Peers
100
S&P
6
11.21HIGH▾
P/FCF?
Peers
100
S&P
90
9.6CHEAP▾
EV/EBITDA?
Peers
100
S&P
21
21.4HIGH▾
EV/Sales?
Peers
100
S&P
3
14.47HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
43
11.9%FAIR▾
ROA?
Peers
50
S&P
37
4.1%FAIR▾
Cash Flow & Enterprise
FCF?$3.0B
Enterprise Value?$36.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist